Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amplimexon + Gemcitabine in Metastatic Pancreatic Cancer
NCT00637247Phase 2Completed
- Sponsor
- AmpliMed Corporation
- Start
- Apr 2008
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of imexon in pancreatic adenocarcinoma (PDAC), sponsored by AmpliMed Corporation. Started Apr 2008; status: completed.
02
Drugs
imexon
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00637247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00637247.